





















Administration of muscarinic antagonists induce 
changes in passive avoidance learning and in synaptic 
transmission in the CA1 area of the hippocampus
Yulia V. Dobryakova*, Olga Y. Ivanova and Vladimir A. Markevich
Neurophysiology of Learning Lab, Institute of Higher Nervous Activity and Neurophysiology Russian Academy of Science, Moscow, Russia 
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Muscarinic acetylcholine receptors (mAChR) are known to be related to learning and memory processes. Inactivation of mAChR 
by cholinergic antagonists have been shown to produce amnesia in a variety of behavioral tasks. In this study, we investigated the 
role of M1 and M2 AChR on passive avoidance learning and plasticity of synapses formed by Schaffer collaterals in freely moving 
rats. Experiments were performed using Wistar male rats. Seven  days before testing, a  recording electrode was lowered in the 
CA1 region under chloral hydrate anaesthesia to record the field excitatory postsynaptic potential (fEPSP) in response to Schaffer 
collateral stimulation. Selective M2 receptor antagonists methoctramine and selective M1 receptors antagonist pirenzepine were 
intraperitoneally injected immediately after training. The effects on memory retention were examined using passive avoidance 
training. We measured latency of the first entry into a dark compartment of the chamber. fEPSP amplitude and slope ratio were 
measured before shock presentation, 90 min after the shock, and 24 hour after the shock. Methoctramine significantly impaired 
behavior in the passive avoidance test but pirenzepine did not induce any changes compared to control. Our results showed that 
pirenzepine but not methoctramine supressed the amplitude of fEPSPs. On the other hand, intracerebroventricular methoctramine 
administration impaired passive avoidance learning and increased the amplitude of fEPSP. 
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INTRODUCTION
Acetylcholine (ACh) is involved in modulation of 
neuronal excitability, synaptic transmission, and plas‑
ticity in the hippocampus (Cobb and Davies 2005) and 
classically excites pyramidal cells (Cole and Nicoll 1983, 
Dodd et al. 1981). The hippocampus is the main structure 
that is involved in different forms of learning, memory, 
and synaptic plasticity (Bliss and Collingridge 1993, Iz‑
quierdo et al. 2002). Previous studies have shown that 
each region of the hippocampus is associated with var‑
ious types of memory, such as episodic, contextual or 
working memory. It is known that the CA1 region of the 
hippocampus is involved in memory formation process‑
es. Immediate, but not delayed, intra CA1 infusions of 
the selective muscarinic agonist oxotremorine improves 
memory, whereas scopolamine has an amnestic effect in 
passive avoidance (PA) learning (Izquierdo and Medina, 
1997). Synaptic processes in this region are strongly reg‑
ulated by cholinergic inputs and it appears that musca‑
rinic but not nicotinic receptors play the leading role in 
the modulation of these processes (Dasari and Gulledge 
2011, Fernández de Sevilla et al. 2002). 
There are five subtypes of muscarinic acetylcholine 
receptors (mAChR) and all of them are expressed in the 
hippocampus (Drever et al. 2011, Flynn et al. 1995). The 
major subtypes of muscarinic receptors within the cen‑
tral nervous system (CNS) are muscarinic M1, M2 and 
M4 (Drever et al. 2011). Recent findings from single cell 
analysis revealed that, in the hippocampus, muscarin‑
ic M1 receptors are located on CA1 pyramidal cells. M2 
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receptors are expressed by interneurons (Zeisel et al. 
2015) and are present on septo‑hippocampal cholinergic 
terminals (Drever et al. 2011, Rouse et al. 2000, Zhang 
et al. 2002). According to Zeisel et al. (2015), M4 recep‑
tors localize not only to interneurons (like M2 receptors) 
but also to pyramidal cells. M1 receptors are coupled to 
Gq/11‑protein and muscarinic agonists can activate phos‑
pholipase C and increase the level of intracellular Ca2+. 
In contrast, M2 and M4 receptors are coupled to Gi/o‑pro‑
tein and their activation reduces activity of adenylate 
cyclase, which leads to reduction of cAMP levels (Drever 
et al. 2011, Lanzafame et al. 2003). 
Many studies, using brain slices, have shown that 
the involvement of muscarinic receptors in the induc‑
tion of long‑term potentiation (LTP), particularly in 
Schaffer collaterals (SC/C) and the CA1 region. It was 
shown that application of the muscarinic agonist car‑
bachol (CCh) enhances LTP or induces LTP by itself (Au‑
erbach and Segal 1994, 1996, Shinoe et al. 2005) and an‑
tagonists disrupt LTP (Sanchez et al. 2009). In slices of 
M2 knockout mice LTP was significantly reduced com‑
pared to wild types (Seeger et al. 2004). Participation of 
mAChR in the regulation of LTP was also shown in stud‑
ies in vivo. Stimulation of the septum in anesthetized 
rats induced LTP in CA1 (Markevich et al. 1997, 2007) 
and this potentiation was blocked by the non‑selective 
acetylcholine receptor antagonist scopolamine and M1 
receptor antagonist pirenzepine (Ovsepian et al. 2004). 
M2 muscarinic antagonist administration enhanced 
synaptic transmission in the CA1 area in vivo (Hayes et 
al. 2008). However, all these studies did not reveal any 
relationships between changes in synaptic plasticity 
and behavior.
Many studies have suggested a role of musca‑
rinic receptors in learning and memory processes. 
For instance, scopolamine and pirenzepine, antago‑
nists of muscarinic receptors, significantly impaired 
short‑term memory performance and spatial cogni‑
tion in the delayed non‑matching to position test and 
in the 8‑arm radial maze task when given before test‑
ing (Aura et al. 1997, Mishima et al. 2000). M2‑ and M2/
M4‑knockout mice showed an impairment in fear‑as‑
sociated learning in a PA task (Tzavara et al. 2003). 
Nevertheless, some papers indicated that muscarinic 
M2 receptor selective antagonist methoctramine could 
improve short‑term memory performance in delayed 
non‑matching to position test (Aura et al. 1997). Only 
a few papers showed the relation between mAChR‑de‑
pendent synaptic plasticity and learning. One of the 
papers showed that spatial working memory was af‑
fected by the M1 antagonist pirenzepine but the drug 
did not induce any changes in the CA1 LTP in anes‑
thetized animals (Kikusui et al. 2000). Another study 
demonstrated that cholinergic facilitation of hippo‑
campal LTP in the walking animals in vivo was blocked 
by pirenzepine (Doralp and Leung 2008).
Therefore, we designed our study to investigate 
the role of muscarinic M1 and M2 receptors in synap‑
tic plasticity and reconsolidation of memory traces in 
freely moving rats. Our laboratory previously reported 
that the non‑selective muscarinic antagonist scopol‑
amine reduced the synaptic plasticity of the SC/C syn‑
apses but had no effect on the memory retention in the 
PA task (Dobryakova et al. 2014). Since scopolamine is 
a non‑selective muscarinic antagonist, we analyzed 
the effects of two more specific drugs, methoctramine, 
a selective muscarinic M2 receptor antagonist, and 
pirenzepine, a selective muscarinic M1 receptor antag‑
onist, on PA learning and synaptic plasticity in freely 
moving rats. 
METHODS
The experiment was performed using adult male 
Wistar rats (250‑300 g) received from Reasearch Center 
of Biomedical Technology RAMS, nursery “Pushchino”. 
A total of 78 rats were used in this study (n=5‑10/group). 
Animals were housed under standard conditions at 
21±1°C with a 12 h light/dark cycle, food and water were 
provided ad libitum. All experiments were performed in 
accordance with the ethical principles stated in the Eu‑
ropean directive (86/609/EC) and were approved by the 
Ethical Committee of the Institute of Higher Nervous 
Activity and Neurophysiology of the Russian Academy 
of Sciences. 
Stereotaxic surgery
Neurophysiological and behavioral studies were 
preceded by surgical operation. Rats were intraperi‑
toneally (i.p.) anaesthetized with chloralhydrate (400 
mg/kg) and mounted in a Kopf stereotaxic frame. A bi‑
polar nickel‑chrome electrode (diameter 80 microm‑
eters) was implanted into the brain for Schaffer‑col‑
lateral pathway (3.0 mm posterior, 3.0 mm lateral to 
bregma, approximately 2.8 mm ventral to dura) stim‑
ulation (Paxinos and Watson 1998). To record field ex‑
citatory postsynaptic potential (fEPSP) in response to 
paired pulse stimulation a recording nickel‑chrome 
electrode was lowered into the CA1 area (2.7 mm pos‑
terior, 1.5 lateral to bregma, approximately 2.2 mm 
ventral to dura) (Paxinos and Watson 1998). The breg‑
ma and lambda were at the same horizontal level. No 
differential lead was used, therefore, one electrode in 
the frontal bone served as a ground and as a reference 
electrode. The electrodes were fixed to the skull using 
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quick‑setting dental plastic (protakril M) and stainless 
steel screw. Rats were allowed to recover for 7 days af‑
ter the surgery. 
Passive avoidance (PA) learning 
To study the effect of muscarinic antagonists on the 
formation of PA we used the dark‑light chamber para‑
digm. The test apparatus (OpenScience, Russia) consist‑
ed of a plastic box equally divided into two compart‑
ments (30cm×30cm×30cm): one was white‑colored and 
brightly illuminated and the other one was black‑col‑
ored and dark. The two compartments were not sepa‑
rated by door.
Behavioral procedures
On day 1, during the first testing, rats were placed 
into the light compartment and allowed to move 
freely between the two parts of the chamber for 
5 min (habituation trial). After the habituation trial, 
the fEPSP initial slope was recorded for 30 min in an 
individual recording cage. Immediately after the fEP‑
SP recording rats were placed into the same chamber 
(acquisition trial), behavioral conditions were simi‑
lar to the habituation trial but entry into the dark 
compartment was paired with a 10‑sec electric shock 
(0.5 mA) provided through the metal grid covering 
the floor of the test camera. 
After the shock, rats were immediately removed 
from the apparatus, received an intraperitoneal in‑
jection (1 ml/kg) of saline, methoctramine hydrate 
2 mg/kg (Sigma‑Aldrich) or pirenzepine 1 mg/kg (Sig‑
ma‑Aldrich) (dissolved in sterile 0.9% NaCl) and were 
placed into the recording cage for the fEPSP registra‑
tion (90 min). On day 2, during the retention trial, no 
foot shock was given and the step‑through latency was 
recorded as a measure of retention. Before and after 
that rats were placed into the recording cage for fEPSP 
registration (30 min). 
In additional experiments, rats received intrace‑
rebroventricular (i.c.v.) infusions of methoctramine 
(12.5 µg/rats). Guide cannulas were lowered into the 
ventricle (0.8 mm posterior, 1.5 lateral to bregma) 
(Paxinos and Watson 1998). Drug (2 µl) was infused 
at a rate of 0.2 µl/min. Infusing cannula was attached 
to a polyethylene tubing (Corning Corporation, USA), 
which was attached to a 10 µl Hamilton syringe (Ham‑
ilton company, USA). Drug administration was con‑
trolled by a microinfusion pump (Stoelting Co., USA). 
The location of the infusion sites were then histologi‑
cally confirmed. 
Histology 
Rats were anaesthetized with chloralhydrate 
(400 mg/kg, i.p.) followed by intracardiac perfusion of 
0.9% NaCl and then 4% formalin (Sigma‑Aldrich, USA). 
Brains were removed and placed in a 4% formalin solu‑
tion in PBS for at least 5 days. After that, brains were 
placed in a 20% sucrose solution on PBS for at least 
24 h. Coronal sections (20 µm thick, proximal to in‑
jection and electrodes tracks) were sliced at ‑18°C us‑
ing a cryostat (Zeiss, Microm HM560). Cannula place‑
ments were verified using Nissl staining. Cannula and 
electrodes placement were found to be correct in 95% 
of the animals (within the limits of 1 mm3 of the inser‑
tion sites).
The methoctramine dose for intraperitoneal injec‑
tions (2 mg/kg) was based on our pilot behavioral exper‑
iments. The dose of the drug for intracerebroventricu‑
lar (i.c.v.) administration (12.5 µg/rat) was chosen from 
previous data (Aura et al. 1997). The dose of pirenzepine 
(1 mg/kg, i.p.) was selected on the basis of previous data 
(Witkin et al. 1988) and data of our pilot behavioral ex‑
periments in the PA task.
Electrophysiology 
For habituation to the experimental conditions, 
each rat was housed in the individual recording cage 
for 30 min prior to the start of the field EPSPs record‑
ing session. The amplitude of the fEPSPs was measured 
in freely moving rats during the first 90 min after the 
trial and saline/methoctramine/pirenzepine injection 
(consolidation period) and 24 h after (memory reten‑
tion test). 
The fEPSP amplitude in the CA1 field evoked by 
stimulation of the Schaffer collaterals (interstimulus 
interval 30 msec; intertrain time 20 sec at intensity 
of 100‑400 μA) was obtained from 10 succesive stimuli 
and was recorded every 10 min. The test paired pulse 
intensity was set to evoke 40‑50% of maximum fEPSP 
amplitude. The efficacy of synaptic transmission was 
evaluated based on changes in the amplitude charac‑
teristics of the evoked responses in the hippocampal 
CA1 field in response to test stimulation of the Schaffer 
collaterals.
Statistical analysis 
All data are presented as mean ± SEM. Across groups 
of electrophysiological data, statistical significance be‑
tween means was determined using a mixed‑design 
analysis of variance followed (where applicable) by 
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Fisher’s Least Significant Difference (LSD) post hoc test to 
reveal group differences on separate time intervals; for 
within the group comparisons, a paired Student’s t‑test 
was used. The differences in behavioral parameters were 
analyzed by the Mann‑Whitney U‑test and χ2 criterion. 
RESULTS
We tested PA behavior in five groups of rats that re‑
ceived methoctramine (2 mg/kg, i.p. and 12.5 μg, i.c.v.), 
pirenzepine (1 mg/kg, i.p.) and saline (i.p. and i.c.v.) 
(Fig. 1). Since saline i.c.v. injected rats had PA learning 
parametrs similar to saline i.p. rats, we combined the 
results of these two control groups. In contrast to both 
doses of methoctramine, which reduced the latency to 
enter the dark chamber, there were no differences be‑
tween latencies obtained after injections of saline or 
pirenzepine (Fig. 1). Thus, selective M2 muscarinic an‑
tagonist methoctramine at doses of 2 mg/kg (i.p.) and 
12.5 μg (i.c.v.) was able to reduce latency to enter the 
dark chamber compared with selective M1 antagonist 
pirenzepine and to control group (91.1±48.9 sec (n=8), 
98.1±47.9 sec (n=8), 206.25±37.9 sec (n=12), 228.6±28.8 sec 
(n=19), accordingly, χ2=5.53, P<0.05). 
Next, we examined the effects of muscarinic antag‑
onists (metoctramine, pirenzepine) on fEPSP evoked by 
Schaffer collateral stimulation. Under our experimental 
conditions, fEPSPs were stable for at least 1 hour (data 
not shown). Mixed design ANOVA did not show signif‑
icant effect of training on fEPSP amplitude (F1,42=1.0, 
P<0.3). However, significant differences were found for 
the drug treatment (F2,42=3.41, P<0.04). Furthermore, 
a significant time and drug interaction (F24,504=1.7, P<0.02) 
suggested that decrement in fEPSP amplitude over time 
is related to the drug action. Subsequent ANOVA for the 
separate conditions followed by post hoc revealed that 
pirenzepine induced a significant reduction of the fEPSP 
characteristics over time (an average decrease of 15%, 
Fisher’s LSD; P<0.05) (Fig. 2A, C). 
Since systemic (i.p.) methoctramine injection did 
not affect the fEPSPs amplitude in the CA1 region of the 
hippocampus, we further used an intracerebroventicu‑
lar methoctramine administration to clarify brain‑spec‑
Fig. 1. Effect of methoctramine (n=8) and pirenzepine (n=12) on passive avoidance learning. Trained rats that received systemic (2 mg/kg) or i.c.v 
(12.5 μg/rat) methoctramine (n=8) had a significant shorter latency to enter the dark chamber than trained‑saline (n=19) or trained‑pirenzepine 
rats. *, significant difference against the saline group, p<0.05.
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ificity of the M2 muscarinic antagonist action. Similar 
to i.p. injected animals, there were no significant dif‑
ferences in the amplitude of the fEPSPs between the 
untrained and trained rats (F1,24=0.16, P<0.7). However, 
there was a main effect of drug (F1,24=1.4, P<0.05). The 
rats from i.c.v. methoctramine treated group had signifi‑
cantly higher amplitude of fEPSPs compared to control 
(Fig. 2B, D). A significant interaction between drug and 
time (F12,288=2.33, P<0.01) were found for the fEPSP am‑
plitude. The amplitude in methoctramine‑treated rats 
were higher and increased over time independently of 
training conditions.
We also assessed the effects of the antagonists 
on fEPSPs during the retention period (24 hour after 
the training and before and after placement into the 
light‑dark chamber). At 24 hours, the fEPSP magnitude 
was not significantly different from the basal values 
in saline‑treated trained and untrained rats. Howev‑
er, we found that, at 24 hours, in untrained rats i.p. 
methoctramine significantly increased the fEPSP am‑
plitudes before placement into the light‑dark chamber 
(115.7±6.6% compared with basal level, P<0.05; Fig. 3A). 
In trained rats treated with methoctramine, the fEPSP 
amplitude also tended to increase (120.1±10.0% be‑
fore camera session compared with baseline, P<0.06; 
Fig. 3B). In pirenzepine‑treated untrained and trained 
animals the magnitude of fEPSPs was higher compared 
to the basal level but these changes were not signifi‑
cant (Fig. 3A, B).
DISCUSSION
Here, we investigated the role of specific mAChR 
ligands on memory consolidation in the passive avoid‑
ance task and their relationship with fEPSP in the CA1 
area in freely moving rats after intraperitoneal ad‑
ministration of the drugs. Our results have shown that 
i.p. injections of the selective M2 antagonist methoc‑
tramine induced a deficit in a PA learning. Howev‑
er, antagonism of M1 muscarinic ACh receptors by 
pirenzepine did not affect memory in this task. Pre‑
Fig. 2. Effect of methoctramine and pirenzepine on field excitatory postsynaptic potential (fEPSP) in the hippocampal CA1 region. (A), the time course of 
fEPSP in methoctramine (n=7), pirenzepine (n=8) and saline groups (n=10) for 90 min after intraperitoneal injection in untrained rats. (B) The time course 
of fEPSP in i.c.v. methoctramine and i.c.v. saline groups (n=8) for 90 min in untrained rats. (C, D) The fEPSP in vivo varies as a function of the drug treatment 
in the intact rat CA1 region. Each point represents the mean ±S.E.M. percentage of basal fEPSP amplitude at 0 min; *, significant differences against the 
saline group, P<0.05. 
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vious studies have reported that different muscarinic 
antagonists were used to modulate behaviour and in‑
duced similar effects in various behavioral tests. For 
instance, posttraining scopolamine administration 
inhibited long‑term memory in inhibitory avoidance 
task (Bianchin et al. 1999). Methoctramine and piren‑
zepine disrupted operant responding (Cousens and 
Beckley 2007, Witkin et al. 1987, 1988).
Thus, the effect of methoctramine may be explained 
by the M2 receptor localization and selective M2 antag‑
onist action (Drever et al. 2011). M2 receptors are pres‑
ent on cholinergic terminals where they regulate ACh 
release (Zhang et al. 2002). Therefore, we assumed that 
regulation of ACh release is associated with modulation 
of behavioral processes underlying performance of the 
PA task. In support of our i.p. results we have shown that 
i.c.v. injection of methoctramine (12.5 μg) also impaired 
PA learning. Thus, our data suggest that M2 receptors 
mediate a memory consolidation processes and that 
methoctramine at the doses used act via centrally locat‑
ed receptors. 
In contrast to the previous studies where the M1 an‑
tagonist, pirenzepine, impaired long‑term memory in 
operant task in rats (Witkin et al. 1987, 1988), in our 
paradigm of fear‑associated learning pirenzepine did 
not induce any changes. The lack of the drug effects on 
PA learning may be ascribed to its hydrophilic proper‑
ties, which limited CNS access of the drug via the blood 
brain barrier. It also appears that learning in this task 
is less sensitive to a low dose of i.p. pirenzepine ad‑
ministration. It was previously shown that the effects 
of i.p. pirenzepine in a PA task are dose‑dependent 
and a much higher systemic dose is needed to disrupt 
PA learning (Worms et al. 1989). Further experiments 
are needed to determine the effects of i.c.v. pirenze‑
pine for a proper comparison with the methoctramine 
data. However, in the studies mentioned above pirenze‑
pine was injected 30 min before the task and it was not 
clear which phase of learning was affected: perception, 
memory formation or memory consolidation. Here, 
we injected the drug during the consolidation period, 
hence, our results suggest that pirenzepine does not af‑
fect consolidation of fear‑associated memory. The dif‑
ferences in these results might be related to different 
experimental conditions. 
It was previously hypothesized that cholinergic sys‑
tem is involved in memory and learning processes via 
modulation of synaptic plasticity. Thus, fEPSP charac‑
teristics can change during different stages of learning. 
However, even during in vivo studies the effect of the 
cholinergic agents on LTP was not tested simultaneous‑
ly with behavior (Hoelscher et al. 1997, Markevich et al. 
1997). Here we used the PA learning which is fear‑asso‑
ciated and hippocampus‑dependent test. We suggested 
that changes in hippocampal CA1 fEPSPs induced by 
muscarinic antagonists are dependent of the changes in 
learning processes in our behavioral test. 
The lack of differences in the parameters of PA learn‑
ing does not exclude the possibility that pirenzepine 
can affect synaptic transmission. Our data indicate that 
systemic administration of pirenzepine decreased fEP‑
SP 90 min after drug administration. This findings is in 
agreement with previous studies showing that M1‑selec‑
tive antagonists pirenzepine and telenzepine suppressed 
the amplitude of LTP (Luo et al. 2008). This indicates that 
pirenzepine, at the dose used (1 mg/kg, i.p.), binds di‑
rectly to M1 receptors and affects basal synaptic trans‑
mission in the CA1 hippocampal region. 
In contrast to the M1‑selective antagonist, i.p. ad‑
ministration of methoctramine did not induce any 
Fig.  3. The effect of methoctramine (2  mg/kg) (n=6) and pirenzepine 
(1 mg/kg) (n=6) on the Schaffer collaterals fEPSP amplitude in untrained 
(A) and trained rats (n=8 in methoctramine group, n=7 in pirenzepine 
treated rats) (B), in 24  hours after the injection (mean ±S.E.M., N=6–9/
group) before and after the testing of memory retention (retention trial). *, 
significant difference, P<0.05.
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changes in fEPSP characteristics 90 min after the injec‑
tion. However, methoctramine significantly increased 
the fEPSP amplitude 24 h after injection compared to 
baseline. Futhermore, i.c.v. injected drug caused a per‑
sistent enhancement in fEPSPs amplitude immediately 
after injection. According to previously published data, 
several M2‑selective antagonists including methoctra‑
mine (AF‑DX 116 and gallamine) also induced the same 
effect (Hayes et al. 2008, Li et al. 2007). A possible mech‑
anism of this effect is the inhibiton of M2 autorecep‑
tors, regulating ACh release (Hayes et al. 2008, Li et al. 
2007). M2 receptors are located on septo‑hippocampal 
cholinergic nerve terminals (Rouse et al. 2000, Zhang 
et al. 2002). Therefore, the blockade of these autore‑
ceptors induce an increase in ACh release (Carey et al. 
2001, Vannucchi et al. 1997). Another possible mecha‑
nism of the persistent enhancement of fEPSPs ampli‑
tude is that methoctramine can inhibit M2 receptors 
on glutamatergic terminals (Drever et al. 2011). It was 
previously shown that antagonism of M2 receptors can 
increase endogenous glutamate release in the hippo‑
campus (Marchi and Raiteri 1989). 
Methoctramine is considered as a selective M2 recep‑
tor antagonist, however it may block M4 subtype as well. 
M4 receptors are also expressed on interneurons and on 
pyramidal cells (Drever et al. 2011, Volpicelli and Levey 
2004) and can activate the same cascade. It was shown 
that concurrent activation of both muscarinic receptors 
subtypes may be required for changes in memory for‑
mation (Leaderbrand et al. 2016) and plasticity. However, 
the affinity of methoctramine to M4 is smaller compared 
to M2 and its contribution to the observed effects needs 
further investigations. 
Overall, our results suggest that methoctramine 
affected memory consolidation in the PA task but en‑
hanced the amplitude of basal synaptic transmission. 
Meanwhile, pirenzepine did not change consolidation 
of fear‑associated memory but reduced the fEPSP am‑
plitude. Our findings is in agreement with Kikusui et al. 
(2000) who have shown that spatial working memory 
in allocentric place discrimination task is affected by 
muscarinic antagonists but is independent from CA1 
LTP. However, it has been discussed in several previ‑
ous studies that pirenzepine blocked the facilitation 
of LTP induced during walking in freely behaving rats 
(Doralp et al. 2008) and affected LTP that is required 
for the formation of place representation (Dragoi et al. 
2003). Thus, it is possible that the described changes 
in the efficacy of synaptic transmission and PA learn‑
ing could be mediated by different mechanisms and are 
dependent on doses and types of methoctramine and 
pirenzepine administration. Perhaps, the behavioural 
effects of antagonists and synaptic changes have differ‑
ent sensitivity to the doses used.
In conclusion, our results showed that memory con‑
solidation after PA learning is dependent on the musca‑
rinic cholinergic system but it had no direct connection 
with the hippocampal CA1 fEPSP.
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